Russian courts are reshaping corporate structure review for foreign pharmaceutical investors. What in-house counsel must address now. Make an enquiry.
Recent shifts in Russian court practice have introduced a materially different standard for assessing the legitimacy of corporate structures maintained by foreign investors in Russia — and nowhere is this shift more consequential than in the pharmaceutical sector, where regulatory licensing, GMP certification, and foreign ownership interact under frameworks that Russian courts have begun to scrutinise with renewed attention. For in-house counsel managing Russian pharmaceutical subsidiaries or joint ventures in early 2027, the practical implication is clear: corporate structure review is no longer a pre-transaction exercise. It is an ongoing compliance discipline.
For much of the period between 2015 and 2023, Russian courts — primarily the arbitrazh courts and the appellate circuits — applied a broadly permissive standard when reviewing corporate structures established by foreign investors. The operative question was largely formal: was the entity properly registered, were charter documents in order, and were statutory governance requirements met? Substance-over-form analysis, where it appeared at all, was concentrated in tax proceedings brought by the Federal Tax Service.
That position has shifted. Over the course of 2025 and 2026, a discernible line of arbitrazh court decisions — primarily at the cassation level — expanded the scope of corporate structure scrutiny beyond tax contexts. Courts have increasingly applied an economic substance test when evaluating whether a foreign investor's chosen structure is consistent with the stated commercial purpose of the Russian legal entity. In practice, this has meant greater judicial willingness to examine the allocation of management functions between a Russian operating subsidiary and its foreign parent, the content of intercompany service agreements, and whether the Russian entity exercises genuine operational control over its licensed activities.
For the pharmaceutical sector specifically, this development intersects with a regulatory framework that already demands substantive local presence. Licences issued by Roszdravnadzor — Russia's pharmaceutical regulatory authority — are entity-specific and non-transferable. GMP certificates are tied to particular manufacturing sites and the management systems operating within them. When a court examines whether a corporate structure reflects genuine pharmaceutical operations, it is therefore examining a set of facts that the regulatory regime has already partly defined. Courts have, in several documented instances during 2026, declined to afford the standard protections of limited liability where the Russian operating entity was found to lack the management substance that its pharmaceutical licence implicitly required.
The shift is not a wholesale departure from established corporate law principles. Russian corporate legislation continues to protect the separate legal personality of registered entities. What has changed is the evidentiary standard courts apply when that personality is challenged — whether in creditor proceedings, regulatory disputes, or governance litigation brought by minority shareholders. The threshold for demonstrating economic substance has risen, and the pharmaceutical sector's specific licensing architecture means that foreign investors in this industry face that higher threshold more frequently than counterparts in less regulated sectors.
The most directly affected category is foreign companies that operate in Russia through a single-entity subsidiary — a wholly owned limited liability company or joint stock company — that holds the pharmaceutical licences and GMP certificates but relies on the foreign parent or a regional holding company for day-to-day management decisions, treasury functions, compliance oversight, and regulatory affairs personnel.
This structural model — prevalent among European and Asian pharmaceutical groups that entered the Russian market during the 2010s — was commercially rational when adopted. It minimised administrative duplication and kept governance authority within a centralised regional structure. Under the heightened judicial scrutiny that has emerged from 2025 onwards, however, it presents a profile that Russian courts have identified as warranting examination: a licensed Russian entity whose operational centre of gravity sits outside Russia.
A secondary category — equally relevant for in-house counsel — is foreign investors in pharmaceutical joint ventures where the Russian co-venturer holds the licence but the joint venture agreement concentrates commercial decision-making in a joint committee with significant foreign-party influence. Courts reviewing such structures in the context of creditor or shareholder disputes have examined whether the licence-holding entity is, in practice, acting as an independent commercial operator or as a conduit for directions issued by the foreign participant.
For in-house counsel at multinational pharmaceutical groups, the regulatory timeline here provides limited margin for delay. The licensing renewal cycles that govern most pharmaceutical operations in Russia create predictable windows when Roszdravnadzor and, increasingly, the courts may revisit the substance questions that attach to the licence-holding entity's structure. A corporate structure that was adequately documented three years ago may not withstand the evidentiary standard applied in a 2027 licensing renewal context or a concurrent civil dispute.
If your Russian pharmaceutical subsidiary is approaching a licensing renewal or is subject to ongoing litigation or creditor proceedings — make an enquiry: info@vetrovpartners.com |
"The pharmaceutical sector presents a compounded risk profile: the licensing framework independently requires the kind of local substance that courts are now also demanding in a corporate governance context — meaning that a structure deficiency surfaces simultaneously in regulatory and judicial proceedings." — Vitaliy Vetrov, Managing Partner, Vetrov & Partners
The immediate priority is a structured review of the Russian operating entity's governance documentation against the substance standard that Russian courts have applied in the most recent line of decisions. This is not a standard legal health-check. It requires specific attention to three areas.
First, management function mapping. The review should establish, with documentary support, which management decisions — particularly those touching on the pharmaceutical business: quality management, regulatory submissions, manufacturing oversight, distribution authorisation — are being made by officers resident in Russia and recorded as decisions of the Russian legal entity. Where those decisions are in practice made at a foreign-parent level and merely ratified by the Russian director, that pattern creates the substance deficit that courts have flagged.
Second, intercompany agreement review. Service agreements, management fee arrangements, and cost-allocation structures between the Russian entity and its foreign parent or regional holding company should be reviewed for consistency with the operational reality of the Russian business. Courts have examined these agreements not merely as tax documents but as evidence of whether the Russian entity is genuinely conducting the licensed activity or functioning as a fee-generating pass-through for a foreign group.
Third, licence documentation alignment. The corporate governance documentation — board resolutions, director instructions, internal policies, and the organisational structure disclosed to Roszdravnadzor — should be internally consistent. Inconsistencies between what was represented to the regulatory authority at the time of licence grant and what the corporate documents show about actual management have been a recurring feature of the cases where courts have declined to recognise the full corporate protection of the Russian entity.
A legal due diligence review conducted specifically against the current court practice standard is the appropriate starting point. The firm's prior work on corporate structure review for foreign investors in Russia and the broader analysis of corporate structure review law and practice provide the analytical baseline from which a sector-specific review of pharmaceutical operations can be conducted. Clients with concurrent restructuring concerns should also consider the interaction with Restructuring & Insolvency considerations, particularly where the Russian entity carries intercompany debt. A consolidated view of the firm's relevant matters can be found at /matters/.
The court practice described in this update is not yet codified in a single authoritative ruling from the Supreme Court of the Russian Federation, and the decisions that have shaped the current landscape originate predominantly from the cassation level in the Siberian, Ural, and Central circuits. There is meaningful variation between circuits in how the substance test is articulated, and the degree to which pharmaceutical-sector specificity influences the analysis is not yet uniform.
Two questions remain open in practice. The first is how courts will treat structures where the foreign parent has reduced its day-to-day management role but has done so only recently — that is, whether retrospective restructuring of governance arrangements will be treated as remedial or as evidence of the prior deficiency. Early indications from 2026 decisions suggest that courts take a longitudinal view of substance, examining the arrangement over the duration of the licence period rather than at a single point in time. This makes contemporaneous documentation practices more important than a one-time corrective exercise.
The second open question concerns the interaction between the substance analysis and the EAEU regulatory framework. Russia's membership of the EAEU has produced a set of pharmaceutical authorisation rules that apply across member states and that were developed partly to facilitate cross-border pharmaceutical operations. Whether courts will treat EAEU-authorised structures differently from purely Russian domestic arrangements — given that the EAEU framework itself accommodates certain forms of cross-border management — is a question that remains without definitive resolution. For foreign investors whose Russian pharmaceutical operations are integrated into a broader EAEU supply chain, this uncertainty warrants specific monitoring.
Q: What specifically changed in Russian court practice on corporate structure review in the pharmaceutical sector?
A: Russian arbitrazh courts — particularly at the cassation level — have from 2025 onwards applied a higher evidentiary threshold when assessing whether a foreign investor's corporate structure in Russia reflects genuine economic substance. Previously, substance scrutiny was concentrated in Federal Tax Service proceedings. Courts have broadened the inquiry to corporate and creditor proceedings, examining management function allocation, intercompany agreements, and the consistency of governance documentation with the regulatory representations made to Roszdravnadzor. The pharmaceutical sector is particularly exposed because the licensing framework independently requires local operational presence, meaning the same factual questions arise simultaneously in regulatory and judicial contexts.
Q: Which types of foreign pharmaceutical investors face the greatest exposure under this court practice?
A: The highest-risk profile is a foreign-owned Russian subsidiary — whether a limited liability company or joint stock company — that holds the pharmaceutical licence and GMP certificates but whose management decisions are substantially directed by the foreign parent or a non-Russian regional holding entity. Equally exposed are joint venture structures where the Russian licence-holder operates under a joint committee arrangement with significant foreign-party influence over commercial decisions. Investors with upcoming licensing renewals face the most immediate practical pressure, as Roszdravnadzor processes create a predictable window during which the substance questions can surface in an administrative context concurrent with any civil proceedings.
Q: What should in-house counsel prioritise in response to this development?
A: Three immediate actions: first, map management functions against contemporaneous documentation to establish which decisions are being made, and evidenced as being made, within the Russian legal entity by Russia-based officers. Second, review intercompany agreements for consistency with the operational reality of the Russian business — courts have examined these as evidence of substance, not only as tax instruments. Third, ensure that the governance documentation provided to Roszdravnadzor is internally consistent with the corporate records. A legal due diligence review conducted against the current court-practice standard — not a generic health-check — is the appropriate vehicle for all three exercises.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry